<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094822</url>
  </required_header>
  <id_info>
    <org_study_id>20030123</org_study_id>
    <nct_id>NCT00094822</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the safety and effectiveness of Neulasta®
      (pegfilgrastim) in reducing infection when given on the same day versus one day after the
      completion of chemotherapy (docetaxel and carboplatin) in patients with advanced or
      metastatic non-small cell lung cancer (NSCLC). This study is considered to be
      &quot;investigational&quot; because previous studies with Neulasta® used next day dosing and not same
      day dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of infection</measure>
    <time_frame>during treatment</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PI Discretion</intervention_name>
    <description>PI Discretion</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_label>Pegfilgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced or Metastatic NSCLC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Criteria: - Age 18 years or older - Diagnosis of advanced or metastatic
        non-small cell lung cancer (NSCLC) - Have not received any prior chemotherapy - Have not
        received radiation therapy or undergone major surgery within the past 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2004</study_first_submitted>
  <study_first_submitted_qc>October 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2004</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Neulasta®</keyword>
  <keyword>pegfilgrastim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

